Seek Returns

ILMN vs. RGEN: Illumina vs. Repligen Stock Comparison

How do Illumina (ILMN) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Illumina (ILMN) and Repligen (RGEN)
Profile ItemILMNRGEN
NameIllumina Inc.Repligen Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization32.23 billion USD11.09 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 28, 2000April 29, 1986
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ILMN
RGEN
GSPC
Loading price history…
Illumina (ILMN) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Total Return (1Y)79.70%23.28%
Total Return (3Y, Annualized)28.16%6.20%
Total Return (5Y, Annualized)-10.65%-8.41%

Risk Profile

Drawdown History

ILMN
RGEN
GSPC
Loading price history…
Illumina (ILMN) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Volatility (1Y, Annualized)48.47%46.73%
Beta (5Y)1.461.11
Max Drawdown (5Y)-82.95%-64.67%
Avg. Volume (3M)2.77M1.18M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ILMN and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Sharpe Ratio (1Y)1.560.41
Sortino Ratio (1Y)2.250.60

Profitability

ROE (TTM)

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Illumina (ILMN) at 20.02% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
ROE (TTM)32.39%-0.57%
ROA (TTM)8.32%1.40%
Net Margin (TTM)19.72%-1.47%
Operating Margin (TTM)20.02%6.19%
Gross Margin (TTM)67.68%53.77%

Growth

Revenue Growth

Repligen (RGEN) at 16.36% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Illumina (ILMN) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Revenue Growth (YoY)-0.66%16.36%
Revenue Growth (3Y CAGR)-1.78%-2.70%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)---35.73%

Financial Strength

Current Ratio (MRQ)

Both Illumina (ILMN) at 2.63 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Repligen (RGEN) at 0.33 carries an industry-typical debt-to-equity mix, while Illumina (ILMN) at 0.74 uses more debt funding than most peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Current Ratio (MRQ)2.639.88
Debt / Equity (MRQ)0.740.33
Net Debt / EBITDA0.85-1.19

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Illumina (ILMN) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): RGEN does not report P/E ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Illumina (ILMN) at 7.10 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Illumina (ILMN) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Repligen (RGEN)
MetricILMNRGEN
P/E Ratio (TTM)36.68--
P/S Ratio (TTM)7.1013.77
P/B Ratio (MRQ)10.304.70
Free Cash Flow Yield (TTM)2.67%1.01%